Table 4.
Clinical and serological features of patients treated with tocilizumab.
| Tocilizumab(n=30) | Standard of care(n=103) | p value | PaO2/FiO2 ratio ≥ 100 mmHg | PaO2/FiO2 ratio < 100 mmHg | |||||
|---|---|---|---|---|---|---|---|---|---|
| Tocilizumab(n=18) | Standard of care(n=59) | p value | Tocilizumab(n=12) | Standard of care(n=44) | p value | ||||
| Age (years) | 62.5 (53-74) | 62 (57-72) | 0.86 | 58 (51-73) | 61 (55-71) | 0.56 | 72 (59-74) | 63 (58-73) | 0.56 |
| Male sex, n (%) | 18 (60%) | 57 (55%) | 0.68 | 12 (67%) | 38 (64%) | 0.99 | 6 (50%) | 19 (43%) | 0.75 |
| Comorbidities | |||||||||
| HBP | 12 (40%) | 44 (43%) | 0.83 | 7 (39%) | 22 (37%) | 0.99 | 5 (42%) | 23 (52%) | 0.75 |
| CAD | 3 (10%) | 18 (17%) | 0.4 | 0 (0%) | 10 (17%) | 0.1 | 3 (25%) | 8 (18%) | 0.69 |
| Type 2 diabetes | 4 (13%) | 21 (20%) | 0.44 | 2 (11%) | 10 (17%) | 0.72 | 2 (17%) | 11 (25%) | 0.71 |
| COPD | 1 (3%) | 7 (7%) | 0.68 | 0 (0%) | 3 (5%) | 0.99 | 1 (8%) | 4 (9%) | 0.99 |
| Cancer | 2 (6%) | 8 (8%) | 0.99 | 1 (5%) | 7 (12%) | 0.67 | 1 (8%) | 1 (2%) | 0.39 |
| CRF | 3 (10%) | 7 (7%) | 0.69 | 0 (0%) | 3 (5%) | 0.99 | 3 (25%) | 4 (9%) | 0.16 |
| PaO2/FiO2 ratio (mmHg) | 111 (84-181) | 121 (91-221) | 0.83 | 176 (117-187) | 172 (127-229) | 0.35 | 81 (70-86) | 73 (61-86) | 0.26 |
| Laboratory values | |||||||||
| LAD (125-220 IU/L) |
441 (358-552) | 474 (383-606) | 0.39 | 443 (354-552) | 415 (377-540) | 0.66 | 438 (362-583) | 565 (436-726) | 0.08 |
| CRP (< 6 mg/L) | 143 (92-212) | 167.6 (124-231) | 0.17 | 124 (68-187) | 153 (123-192) | 0.09 | 186 (139-234) | 202.6 (135-238) | 0.77 |
| Ferritin (30-400 ng/mL) |
1400 (1054-2654) | 2260 (1237-3450) | 0.1 | 1433 (1104-3079) | 2326 (1254-3215) | 0.47 | 1228 (789-2573) | 1717 (1198-3871) | 0.07 |
| IL6 (<7 pg/mL) | 69 (50-456) | 68.9 (34-162) | 0.73 | 56 (29-229) | 51 (26-116) | 0.71 | 45 (24-52) | 105 (66-286) | 0.11 |
Results are reported as median (interquartile range) unless specified; statistically significant p value < 0.05. HBP, high blood pressure; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; LAD, lactate dehydrogenase; CRP, C-reactive protein; IL-6, interleukin-6.